Cognitive Decline in Patients with Alzheimer's Disease
A special issue of Brain Sciences (ISSN 2076-3425). This special issue belongs to the section "Neurodegenerative Diseases".
Deadline for manuscript submissions: closed (25 October 2023) | Viewed by 279
Special Issue Editors
Interests: Alzheimer’s disorder; depression; neurodegeneration; CNS aspects of type II diabetes mellitus; behavior pharmacology; molecular docking and simulation; molecular pharmacology; proteomics
Interests: Alzheimer’s disorder; depression; neurodegeneration; CNS complications; diabetes mellitus; behavior pharmacology; molecular docking and simulation
Special Issue Information
Dear Colleagues,
Alzheimer’s disorder (AD) is rapidly becoming a global epidemic, with therapeutic management and preventive strategies remaining a true conundrum for clinicians. Despite tremendous advancements in healthcare technologies in recent times, the prevalence of AD is showing exponential growth, which is primarily due to its poorly understood pathophysiology along with multiple pathways working in harmony towards the development and progression of the disease. The absence and validation of biomarkers, poor diagnosis, poor patient compliance, lack of awareness, socio-economic constraints, and caregiver burden further add to the woes of management of cognitive decline in AD. There is now a real need to develop and validate biomarkers, investigate feasible treatment options, explore newer drug targets, and explore diagnostic options which may provide safe and efficacious management for AD.
In this Special Issue, we would like to invite authors to submit their manuscripts that will offer readers an in-depth analysis of the latest advancements in AD research, with the aim of developing new therapeutic, diagnostic, and prognostic options for this challenging—but certainly not hopeless—population.
Dr. Mehta Vineet
Dr. Arun Parashar
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Brain Sciences is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2200 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- Alzheimer’s disease
- cognitive decline
- neurodegeneration
- biomarkers for Alzheimer’s
- caregiver burden
- clinical pharmacology
- neuropharmacology
